Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors
Abstract Linagliptin is a dipeptidyl Peptidase-4 (DPP-4) inhibitor that inhibits the degradation of glucagon-like peptide 1 (GLP-1), and has been approved for the treatment of type 2 diabetes (T2D) in clinic. Previous studies have shown linagliptin improves β cell function using animal models and is...
Guardado en:
Autores principales: | Yanqing Zhang, Meifen Wu, Wynn Htun, Emily W. Dong, Franck Mauvais-Jarvis, Vivian A. Fonseca, Hongju Wu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/88d07d8e9add4b2fa9564169da40f93b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Linagliptin use in older individuals with type 2 diabetes
por: Pratley RE
Publicado: (2014) -
Single-donor islet transplantation in type 1 diabetes: patient selection and special considerations
por: Tatum JA, et al.
Publicado: (2017) -
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz B
Publicado: (2013) -
Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes
por: Hoimark L, et al.
Publicado: (2012) -
Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment
por: Scott D
Publicado: (2013)